Signadori Bio
Develops in vivo engineered monocyte immunotherapy to treat solid tumours in preclinical stage
€11.1MSeed+
Role not disclosedLoading investors…
Activity from announced rounds
Develops in vivo engineered monocyte immunotherapy to treat solid tumours in preclinical stage